Patients with Estrogen/Progesterone-Receptor-positive and HER2+ are known as “Triple Positive” BC, a different phenotypic entity from Hormone-Receptor-Negative HER2+ BC, with the latter having worse disease-free survival, overall survival and higher risk of recurrence. The gene discussed is NR4A1; the disease is breast cancer.